Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.

Bourla plans to donate his prize money to “projects aimed at preserving the memory of the victims of the Holocaust, with a particular emphasis on the tragedy suffered by the Greek Jewish ...

Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...

Pfizer is testing multiple doses of once-a-day version of its weight-loss pill, after scrapping development of a twice-daily version of the drug in late 2023. "At this point, I'm very cautious ...